VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in
25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin
D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing
cancer, heart disease, and stroke in people who do not have a prior history of these
illnesses. This ancillary study is being conducted among participants in VITAL and will
examine (1) whether vitamin D reduces incident total, non-vertebral fractures, and hip
fractures and (2) whether this reduction is modified by vitamin D levels
Phase:
N/A
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins